Business Context and Reporting Period
This Form 8-K Current Report was filed by Tvardi Therapeutics, Inc. (TVRD) on December 16, 2025. The Company is a Delaware corporation incorporated in 2025, with principal executive offices in Sugar Land, Texas. The filing discloses corporate governance actions taken by the Board of Directors on December 16, 2025, specifically regarding executive compensation and severance arrangements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on non-financial corporate events related to executive compensation.
Material Changes and Corporate Actions
Retention Compensation Grant
The Board approved one-time retention compensation in the form of stock options for named executive officers to incentivize performance during key clinical trials (Phase 1b/2 of TTI-101 in hepatocellular carcinoma and Phase 1 of TTI-109 in healthy volunteers). The grants are as follows:
- Dr. Imran Alibhai (CEO): 47,500 options
- Dr. John Kauh (CMO): 17,500 options
- Dan Conn (CFO): 17,500 options
Vesting Terms: The exercise price equals the closing share price on the grant date. Vesting commences on December 16, 2026. 25% vests on the one-year anniversary of the commencement date, with the remaining balance vesting in 36 equal monthly installments thereafter.
Severance and Change in Control Plan
The Board approved a new Severance and Change in Control Plan applicable to eligible employees, including all named executive officers. Benefits are contingent upon a "Covered Termination" (termination without Cause or resignation for Good Reason) and the execution of a general waiver and release.
Benefits Within Change in Control Period (3 months prior to 12 months post-closing):
- Base Salary: 18 months (CEO), 12 months (CFO/CMO).
- Target Bonus: 150% (CEO), 100% (CFO/CMO).
- COBRA Premiums: Up to 18 months (CEO), 12 months (CFO/CMO).
- Equity: Full acceleration of unvested time-vesting awards.
- PTO: Lump sum payment for unused accrued vacation (CFO only).
Benefits Outside Change in Control Period:
- Base Salary: 12 months (CEO), 10 months (CFO), 9 months (CMO).
- Target Bonus: Pro-rated based on performance and time worked.
- COBRA Premiums: Up to 12 months (CEO), 10 months (CFO), 9 months (CMO).
- Equity: Acceleration of awards scheduled to vest within 24 months (CEO), 10 months (CFO), or 9 months (CMO) post-termination.
Change in Control Acceleration: If equity awards are not assumed or substituted by an acquirer, vesting accelerates in full (at 100% target for performance awards) immediately prior to the transaction.
Guidance, Outlook, and Risks
Outlook: Management commentary indicates a focus on executing the Phase 1b/2 clinical trial of TTI-101 and the Phase 1 trial of TTI-109.
Risks and Contingencies: The filing notes that severance benefits are subject to Section 280G and 4999 of the Internal Revenue Code (excise tax on "parachute payments"). The Plan includes a "best-after-tax" analysis provision to mitigate this risk. The full text of the Severance Plan will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2025.
Investor Verification Checklist
- Verify the closing share price on December 16, 2025, to determine the exercise price of the newly granted options.
- Review the upcoming Form 10-K for the full text of the Severance and Change in Control Plan to understand specific definitions of "Cause" and "Good Reason."
- Monitor clinical trial progress for TTI-101 and TTI-109, as these are the stated drivers for the retention compensation.
- Assess the potential dilution impact of the 82,500 new options granted to executives.